Skip to content
Screener

Arbutus Biopharma Corporation ABUS Revenue from collaborations and licenses — Revenue

Other product segments

Collaborations and licenses
$1.32M—
Non-cash royalty revenue
$181K-59.6%

Similar metrics at other companies

RxSight, Inc. logo
RXSTLicense And Collaboration Revenue — Revenue
$6.5M—
4D Molecular Therapeutics logo
FDMTCollaboration And License Revenue — Revenue
$3.05M+21,664%
PTC Therapeutics logo
PTCTCollaboration And License Revenue — Revenue
$143K-100.0%
Kura Oncology logo
KURALicense And Collaboration Revenue — Revenue
$12.5M-11.4%
Cytokinetics logo
CYTKCollaboration Revenues — Revenue
$3.29M+36.2%
Aurinia Pharmaceuticals logo
AUPHLicense, collaboration and royalty revenue — Revenue
$3.81M+10.9%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$896.82M+42.4%
Enterprise value$873.75M+47.1%
P/E5.6×—
P/S4.7×-36.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue
Collaborations and licenses$204$1,316
License revenue from Genevant178,741—
Non-cash royalty revenue181448
Total revenue179,1261,764
Operating expenses
Research and development4,1208,959
General and administrative5,8895,832

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue?
Arbutus Biopharma Corporation (ABUS) reported revenue from collaborations and licenses — revenue of $178.74M in Q1 2026.
How has Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue changed year-over-year?
Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue increased by 21912.4% year-over-year, from $812K to $178.74M.
What is the long-term trend for Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue?
Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue has grown at a 23.0% compound annual growth rate (CAGR), from $4.68M to $10.71M.
What does revenue from collaborations and licenses — revenue mean?
This metric represents the total revenue generated from strategic partnerships, research collaborations, and the licensing of proprietary intellectual property or technology platforms. It reflects the company's ability to monetize its R&D pipeline and technological assets through external commercial agreements.

Ask your AI about Arbutus Biopharma Corporation's revenue from collaborations and licenses — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude